当前位置: X-MOL 学术Nature › 论文详情
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Nature ( IF 42.778 ) Pub Date : 2021-06-09 , DOI: 10.1038/s41586-021-03681-2
Galit Alter, Jingyou Yu, Jinyan Liu, Abishek Chandrashekar, Erica N. Borducchi, Lisa H. Tostanoski, Katherine McMahan, Catherine Jacob-Dolan, David R. Martinez, Aiquan Chang, Tochi Anioke, Michelle Lifton, Joseph Nkolola, Kathryn E. Stephenson, Caroline Atyeo, Sally Shin, Paul Fields, Ian Kaplan, Harlan Robins, Fatima Amanat, Florian Krammer, Ralph S. Baric, Mathieu Le Gars, Jerald Sadoff, Anne Marit de Groot, Dirk Heerwegh, Frank Struyf, Macaya Douoguih, Johan van Hoof, Hanneke Schuitemaker, Dan H. Barouch

The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cellular immune responses from 20 Ad26.COV2.S vaccinated individuals from the COV1001 phase 1/2 clinical trial2 against the original SARS-CoV-2 strain WA1/2020 as well as against the B.1.1.7, CAL.20C, P.1., and B.1.351 variants of concern. Ad26.COV2.S induced median pseudovirus neutralizing antibody titers that were 5.0- and 3.3-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020 on day 71 following vaccination. Median binding antibody titers were 2.9- and 2.7-fold lower against the B.1.351 and P.1 variants, respectively, as compared with WA1/2020. Antibody-dependent cellular phagocytosis, complement deposition, and NK cell activation responses were largely preserved against the B.1.351 variant. CD8 and CD4 T cell responses, including central and effector memory responses, were comparable among the WA1/2020, B.1.1.7, B.1.351, P.1, and CAL.20C variants. These data show that neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.



中文翻译:

Ad26.COV2.S 疫苗针对人类 SARS-CoV-2 变体的免疫原性

Ad26.COV2.S 疫苗1-3已证明对有症状的 COVID-19 具有临床疗效,包括对部分抗中和抗体1的 B.1.351 变体。然而,这种疫苗在人类中针对 SARS-CoV-2 令人担忧的变异体的免疫原性仍不清楚。在这里,我们报告了来自 COV1001 1/2 期临床试验2 的20 名接种 Ad26.COV2.S 疫苗的个体的体液和细胞免疫反应针对原始 SARS-CoV-2 毒株 WA1/2020 以及 B.1.1.7、CAL.20C、P.1. 和 B.1.351 相关变种。在接种疫苗后第 71 天,与 WA1/2020 相比,Ad26.COV2.S 诱导的中值假病毒中和抗体滴度分别比 B.1.351 和 P.1 变体低 5.0 倍和 3.3 倍。与 WA1/2020 相比,针对 B.1.351 和 P.1 变体的结合抗体滴度中值分别低 2.9 和 2.7 倍。抗体依赖性细胞吞噬作用、补体沉积和 NK 细胞激活反应在很大程度上保留了对抗 B.1.351 变体的能力。CD8 和 CD4 T 细胞反应,包括中枢和效应记忆反应,在 WA1/2020、B.1.1.7、B.1.351、P.1 和 CAL.20C 变体之间具有可比性。这些数据表明 Ad26 诱导的中和抗体反应。针对 B.1.351 和 P.1 变体的 COV2.S 减少,但针对 SARS-CoV-2 变体的功能性非中和抗体反应和 T 细胞反应在很大程度上得以保留。这些发现对针对令人关注的 SARS-CoV-2 变体的疫苗保护具有重要意义。

更新日期:2021-06-09
全部期刊列表>>
virulence
欢迎新作者ACS
中国作者高影响力研究精选
虚拟特刊
屿渡论文,编辑服务
浙大
上海中医药大学
深圳大学
上海交通大学
南方科技大学
浙江大学
清华大学
徐晶
张大卫
彭孝军
北京大学
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
华辉
天合科研
x-mol收录
试剂库存
down
wechat
bug